glycyrrhizic acid has been researched along with Uterine Cervical Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ancion, M; Bruyere, D; Delvenne, P; Demoulin, S; Hendrick, E; Herfs, M; Hubert, P; Lebeau, A; Lerho, T; Meunier, M; Nokin, MJ; Peulen, O; Pilard, C; Radermecker, C; Reynders, C; Roncarati, P | 1 |
1 other study(ies) available for glycyrrhizic acid and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Glycyrrhizic Acid; HMGB1 Protein; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Peptide Fragments; RAW 264.7 Cells; S100 Proteins; Signal Transduction; Tumor Burden; Tumor Microenvironment; Uterine Cervical Neoplasms | 2021 |